Amiloidose primária Perspectiva terapêutica
Keywords:
primary amyloidosis, therapeutic alpha-interferonAbstract
The authors emphazise the difficulties in the treatment of primary amyloidosis concerning not only the results but also the problems in evaluating its efficacy. Several therapeutics are reviewed and some considerations are made about the implications of treatment in the desease of yhe organs involved. Finally, they propose the alpha-interferon for treatment of primary amyloidosis.
Downloads
References
Levy Y. Belghiti-Deez D, Sobel A. Traitement de l'amylose sans myeloma Ann Med lntern 1988;139(3):190-193.
Gertz M. Kyle R. Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clin Proc 1986; 61: 218 - 223.
Kyle R. Greipp P, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986: 68(1) 220-224.
Gertz M, Kyle R. Primary systemic amyloidosis - a diagnostic primer. Mayo Clin Proc 1989; 64:1505-1519.
Greipp P. Amyloidosis (AL), an approach to early diagnosis. Arch Intern Med 1984; 2144:2145.
KyleR. Greipp P. Primary systemic amyloidosis: comparision of melphalan and prednisone versus placebo. Blood 1978; 52(4): 818-827.
Stone M. Amyloidosis: a final common pathway for the protein deposition in tissues. Blood 1990;75(3):531-545.
Gertz M. Kyle R. Phase II triai of alpha-tocoferol (vitamin E) in the treatment of primary systemic amyloidosis. Amj Haemat 1990; 34 ( 1): 55-58.
Cohen H. Lessin L, Burkholder P. Resolution of primary amyloi dosis during chemotherapy, studies in a patient with nephro tic syndrome. Ann lntem Med 1975; 82: 466-473.
Fielder K. Durie B. Primary amyloidosis associated with multiple myeloma: predictors of sucessfull therapy. Am J Med 1986; 80: 413-418.
Schaltner A. Varon D, Green L, Hurvitz N, Bentwitch Z. Primary amyloidosis with unusual bone involvement reversibility with melphalan, prednisone and colchicine. Am J Med 1989; 86: 347-348
Schwartz R, Cohen], Schrier L. Theraphy of primary amyloidosis with melphalan and prednisone. Arch Intern Med 1979; 139:1144-1147.
l3. Kyle R, Greipp P. GartonJ, Gertz M. Primary systemic amyloidosis: comparision of melphalan/prednisone versus colchicine. Am J Med 1985; 79:708-718
Kyle R, Wagoner R, Holley K. Primary systernic amyloidosis, resolution of nephrotic syndrome with melphalan and prednisone. Arch Intem Med 1982; 142: 1445-1447.
Galton DA, Babapulle FB. The management of myelomatosis. EurJ Haematol 1987; 39:385- 398.
Gertz NI, Kyle R. Successful treatment of primary amyloidosis Oetter). The authors reply. Mayo Clin Proc 1986; 61: 835-836.
Hawkins P, Lavender P, Pepys M. Evaluation of systemic amyloi dosis by scintigraphy with 123-1-labeled serum amyloid P component. New Engl J Med 1990; 323: 508-513.
Fritz D, Luggen M, Hess E. Unusual longevity in a prymary systemic amyloidosis: a 19 year survivor. Am J Med 1989; 86: 245-248.
Cohen A. Amyloidosis, in Harrison's Principies of internal Medicine, New York, McGraw- Hill, 12.ª ed, 1991: 1417-1421.
Kyle R. Primary systemic amyloidosis. J Intern Med 1992: 232( 6): 523-524.
Alexanian R, Bagsagel D, Migliore P, Vaughn W, Howe C. Mel phalan thelapy for plasma cell myeloma Blood 1968: 31(1); 1-10.
Getz M, Kyle R. Acute leukemia and cytogenetics abnormalities complicating melphalan treatment of primary systemic amyloi dosis. Arch Intem Med 1990; 150: 629-633.
Wolf B, Kumar A, Vera J, Neiman R. Bone marrow morphology and immunologyin systemic amyloidosis. Am J Clin Pathol 1986; 86: 84-88.
Buxbaum J, Hurley M, Chuba J, Spiro T. Amyloidosis of the AL type: clinical, morphologic and biochemical aspects of the therapy with alkylating agents and prednisone. AmJ Med 1979: 67: 867-878.
Buxbaum J. Aberrant imunoglobulin synthesis in light chain amyloidosis. J Clin Invest 1986; 78:798-806.
Alexanian R, Haut A, Khan A, Lane M, Mckelvey E. Migliore P. Stuckey W, Wilson H. Treatment for mtiltiple myeloma, combination chemotherapy with different melphalan dose regiments. JAMA 1969; 208(9): 1680-1685.
Benson M. Treatment of AL amyloidosis with melphalan, preelnisone, and colchicine. Arritis Rheum 1986; 29(5):683-687
Waziéres B, Fest T, Humbert P, Vuitton D, Duponel J. Amylose familiale de type AL et déficit en facteur X, intérêt de la colchicine au long cours. Ann Med lntem 1990; 141(4):388-340.
Manoharan A. Successful treatment of primary amyloidosis Letter). Mayo Clin Proc 1986; 61:835.
Corkery J, Bem MM, Tullis JL. Resolution of amyloielosis and plasma cell elyscrasia with combination chemotherapy (letter). Lancet 1978; 2: 425-426.
McMillan R, Longmire R. Yelenosky R: The effect of corticosteroids on human IgG synthesis. J lmmunol 1976:116 (6): 1592-1595.
Kanoh T. Fatal paralyticus ileus following vinelesine chemotherapy in a patient with myeloma associated amyloidosis. Eur J Haematol 1989: 42(1): 108.
Solomom A, McLaughlin C, Capra J. Bence Jones proteins and light chains of immunoglobulins. XL A transient bence jones related protein associated with corticosteroiel therapy. J Clin Invest 1975; 55: 579-586.
Kanoh T, Nakamura Y, Kawai C. Enhancement of amyloielosis by high-dose pednisolone therapy in multiple myeloma Eur J Haematol 1989; 43 (1 ): 83.
Jones NF, Hilton PJ, Tighe JR, Hobbs JR. Treatment of primary amyloidosis with melphalan. Lancet 1972; 23 Set: 616-619.
Sheehan-Dare R, Simmons A. Amyloid myopathy and myeloma response to treatment. Postgrad Med J 1987; 63:141-142.
Camonano J, Greipp P, Bayer G, Bowie W. Resolution of adquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. New Engl J Med 1987; 316(18):1133-1134.
Nores J, Dalayeun J, Remy J, Nenna A. Évolution sur douze ans d'un plasmocytome multicentrique non excrétant avec amylose. Ann Med Intern 1987; 138(8):679-680.
Michael J, Jones N. Spontaneous remissions of nephrotic syndrome in renal amyloidosis BMJ 1978;1:1592-1593.
Dewald G, Kyle R, Hicks G, Greipp P. Toe clinical significance of cytogenetic studies in 100 patients with multipie myeloma, plasma cell leukemia or amyloidosi. Blood 1985; 66: 466-473.
Majolino I, Marceno R, Pecoraro G, Scime R, Vasta S, Liberti G, Rizzo A, Indovina A, Caronia F. High-dose therapy and auto logous transplantation in amyloidosis-AL. Haemat 1993; 78(1): 68- 71.
Barlogie B, Smith L, Alexanian R. Efective treatment of advanced multiple myeloma refractory to alkylanting agents. New England J Med 1984; 310(21):1354-1356.
Samson D, NewlandA, Keamey J,Joyner M, Mitchell T, BarettA, Gaminara E, Van Pette J, McCarthy D, Aston L, Hamon M, Evans
M. Infusion of vincristine and doxorubicin with oral dexame thasone as first-line therapy for multiple myeloma. Lancet 1989; 14 Oct: 882-885.
Elezovic L Djukanovic R, Rolovic Z. Sucessful treatment of he morragic syndrome dueto anadquired, combined deficiency of factores Vll and X in a patient with multiple myeloma and amyloidosis. Eur J Hemat 1989; 42(1): 105-106.
Editorial: Colchicine in amyloidosis. Lancet 1986; 2(8509): 724-725.
Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gaíni J. Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever. New EnglJ Med 1986; 314:1001-1005.
Cohen A, Rubinow A, Anderson J, Skinner M, MasonJ, Libbey C, Kayne H: Survival of patients with primary (AL) amyloidosis: colchicine treated cases from 1976 to 1983 compared with cases seen in previow years (1961 to 1973). Am J Med 1987; 82: 1182-1190.
Durie B, Perksy B, Scoehnlen B, Grogan T, Salmon S. Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macro phages. New Eng!J Med 1982;307(27):1688-1692.
Glenner G. Amyloid deposits and amyloidosis. The b-fibrilloses. New Engl J Med 1980; 302(24):1333-1341.
Goodmann & Gilman. The Pharmacological basis of therapheu tics. 8.ª ed, Ed. Pergamon Press, 1991.
Rijwijk, Donker J, Ruinen L. Dimethylsulfoxide in amyloidosis. Lancet 1979;27Jan: 207-208.
Tonokunaka S, Osanai H, Morikawa M, Yachiku S. Experience with dimethylsulfoxide treatment for primary localizated amyloidosis of the bladder. J Urol 1986; 135:580-582.
Iwasaki T, Hamano T, Aizawa K, Kobayaski K, Kasishita E. A case of pulmonary amyloidosis associated with multiple myeloma successfully treated with dimethyl sulfoxide. Acta Haematol 1994; 91 (2): 91-94.
Ravid M, Chen B, Bernheim J, Kedar 1. Ascorbic acid-induced regression of amyloidosis in experimental animais. J Exp Path 1985; 66:137-141.
Leinonen H, Sintonen SP. Cardiac amyloidosis, therapeutic and diagnostic difficulties with reference to two different forms of the disease. Acta Med Scand 1986; 219:125-128.
Bouhour JB, Haddalc M, Lefevre M. Le risque des bêta-bloqueurs et des inhibiteurs calciques dans la cardiopathie amyloide Presse Medicale 1986;15(21): 981.
Pollak A, Falk R. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104(2): 616-620.
Greipp P, Kyle R, Bowie W. Factor X deficiency in primary amyloidosis New Engl Med 1979; 301(19):1050-1051.
Rosenstin E, Itzkowitz S, Penziner A, Cohen J, Mornaghi: Resolution of faclor X deficency in primary amyloidosis following splenectomy. Arch Intem Med 1983; 143 597-599
Levin M, Chokas W. Adquired factor X deficiency and amyloidosis treated with melphalan and prednisone. New Engl J Med 1987;317(18): 1155-1156.
Goldstein D, Laszio J. Interferon therapy in cancer from imaginon to interferon. Cancer Res 1986;46:4315-4329.
Roth M, Foon K. Alpha interferon in the treatment of hematologic malignancies. AmJ Med 1986; 81: 871-882.
Bergsagel G. Haas R, Messner A. lnterferon 2-b in the treatment of chronic ganulocytic leukemia, Semin Oncol 1986; 13 (Supl 2) 29-34.
Breenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in asemisolid agar culture system. Scand J Haematol 1985; 35: 178-185.
Breenning G. Ahre A, Nilsson K: Correlation betwveen in vitro and in vivo sensitivity to human leucocyte alpha-interferon in patients with multiple myeloma. ScandJ Haematol 1985; 35: 543-549.
Mandelli F, Avvisali G, Amadori S, Boccadoro M, Gernone A, Lauta V, Marmont F, Tribailo M, Dammaco F, Pilezi A: Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional in duction chemotherapy. New Engln J Med 1990; 322:1430-1434.
Castanzi J, Cooper R, Scarffe J, Ozer H, Grubbs S, Ferraresi R, Pollard R, Spiegel R: Phase II study of recombinant alpha-interferon in resistent multiple myeloma. J Clin Oncol 1985; 3: 654- 659.
Durie B. Chemotherapy of multiple myeloma. Clin Haematol 1991; 4(1): 181-195.
Montuoro A, De Rosa L, De Blasio A, Pacilli L Petti N. Alpha-2.ª interferon/melphalan/prednisone versus melphalan/prednisone in previously unteated patients with multipie myeloma. Br J Haematol 1990; 76:365-368.
Tanaka H, Tanabe O, lwato K, Asaoku H, lshikawa H, Nobuyoshi M, Kawano M, Kuramoto A: Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood 1989; 74(5): 1718-1722.
QuesadaJ, Alexanian R, Hawkins M, Barlogie B, Borden E, ltri L, Gutterman J. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67(2):275-278.
Ehersson H, Eksborg S, Wallin I, Ostreborg A, Mellstedt H. Oral melphalan pharmacokinetics: influence of interferon-induced fever. Clin Pharmacol Ther 1990, 47:86-90.
Parente F, Lopes S, Silva JM, Goncalves L, Mota O, Costa A, Lourenço A, Alexandrino B, Silva PS: Amiloidose Primária - experiência do Serviço de Medicina II dos HUC. Livro de resumos das II Jornadas de Medicina Interna da Zona Sul, 1990.
Parente F, Gonçalves L, Lopes S, Fernandes A, SilvaJM, Simões A, Aleandrino B, Silva PS. A propósito de um caso de amiloidose primária. Arq Med 1993; 7(2): 121-125.
Becherel PA, Boisnic S, Paul C, FermandJP, Frances C. Amylose diffuse: presentation buccale inhabituelle et tentative therapeutique par interferon alpha. Ann Dermatol Venereol 1993; 120 (11): 799-801.
Gertz MA, Kyle R. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Haematol 1993 Oct; 44(2): 125-128.
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
